Eupraxia Pharmaceuticals Inc.
EPRXF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$108.29M
Close$
$0.36
88.2% downside
Current Fair Value
88.2% downsideOvervalued by 88.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $108.29 Million |
|---|---|
| Enterprise Value | $57.81 Million |
| Earnings per Share | $-1.58 |
| Beta | 1.4 |
| Outstanding Shares | 35,622,553 |
Return
| Return on Equity | -45.08% |
|---|---|
| Return on Assets | -42.30% |
| Return on Invested Capital | -47.52% |
Valuation & Multiples
| P/E Ratio | -6.7 |
|---|---|
| PEG | -10.24 |
| Price to Sales | - |
| Price to Book Ratio | 1.01 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.93 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Eupraxia Pharmaceuticals Inc
49 employees
CEO: James A. Helliwell
Eupraxia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm specializing in the discovery, advancement, and commercialization of innovative technologies. Its flagship compound, EP-104IAR, is currently in a Phase II clinical ...